title: T-Cell Therapy: Options for Infectious Diseases.
abstract: The emergence of drug-resistant tuberculosis is challenging tuberculosis control worldwide. In the absence of an effective vaccine to prevent primary infection with Mycobacterium tuberculosis and tuberculosis disease, host-directed therapies may offer therapeutic options, particularly for patients with multidrug-resistant and extensively drug-resistant tuberculosis where prognosis is often limited. CD8(+) and CD4(+) T cells mediate antigen-specific adaptive cellular immune responses. Their use in precision immunotherapy in clinical conditions, especially in treating cancer as well as for prevention of life-threatening viral infections in allogeneic transplant recipients, demonstrated safety and clinical efficacy. We review key achievements in T-cell therapy, including the use of recombinant immune recognition molecules (eg, T-cell receptors and CD19 chimeric antigen receptors), and discuss its potential in the clinical management of patients with drug-resistant and refractory tuberculosis failing conventional therapy.
authors.affiliation: Therapeutic Immunology Division, Department of Laboratory Medicine, Karolinska Institutet.
authors.forename: Shreemanta K
authors.initials: SK
authors.lastname: Parida
authors.affiliation: Therapeutic Immunology Division, Department of Laboratory Medicine, Karolinska Institutet Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Solna, Sweden.
authors.forename: Thomas
authors.initials: T
authors.lastname: Poiret
authors.affiliation: Therapeutic Immunology Division, Department of Laboratory Medicine, Karolinska Institutet.
authors.forename: Liu
authors.initials: L
authors.lastname: Zhenjiang
authors.affiliation: Therapeutic Immunology Division, Department of Laboratory Medicine, Karolinska Institutet.
authors.forename: Qingda
authors.initials: Q
authors.lastname: Meng
authors.affiliation: Division of Clinical Infectious Diseases, German Center for Infection Research, Research Center Borstel.
authors.forename: Jan
authors.initials: J
authors.lastname: Heyckendorf
authors.affiliation: Division of Clinical Infectious Diseases, German Center for Infection Research, Research Center Borstel International Health/Infectious Diseases, University of Lübeck, Germany Department of Medicine, Karolinska Institutet.
authors.forename: Christoph
authors.initials: C
authors.lastname: Lange
authors.affiliation: Therapeutic Immunology Division, Department of Laboratory Medicine, Karolinska Institutet Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Solna, Sweden Department of Medicine, Karolinska Institutet.
authors.forename: Aditya S
authors.initials: AS
authors.lastname: Ambati
authors.affiliation: Therapeutic Immunology Division, Department of Laboratory Medicine, Karolinska Institutet.
authors.forename: Martin V
authors.initials: MV
authors.lastname: Rao
authors.affiliation: Therapeutic Immunology Division, Department of Laboratory Medicine, Karolinska Institutet Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Solna, Sweden.
authors.forename: Davide
authors.initials: D
authors.lastname: Valentini
authors.affiliation: Department of Medicine, Karolinska Institutet.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Ferrara
authors.affiliation: Pancreatic Surgery Unit, Division of Surgery, Department of Clinical Science, Intervention and Technology.
authors.forename: Elena
authors.initials: E
authors.lastname: Rangelova
authors.affiliation: Therapeutic Immunology Division, Department of Laboratory Medicine, Karolinska Institutet Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Ernest
authors.initials: E
authors.lastname: Dodoo
authors.affiliation: Department of Infection, Division of Infection and Immunity, Centre for Clinical Microbiology, University College London National Institute for Health Research Biomedical Research Centre, University College London Hospitals, United Kingdom.
authors.forename: Alimuddin
authors.initials: A
authors.lastname: Zumla
authors.affiliation: Therapeutic Immunology Division, Department of Laboratory Medicine, Karolinska Institutet Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Solna, Sweden.
authors.forename: Markus
authors.initials: M
authors.lastname: Maeurer
mesh_terms: D019264:Adoptive Transfer; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D016207:Cytokines / Q000627:therapeutic use; D054908:Extensively Drug-Resistant Tuberculosis / Q000628:therapy; D006801:Humans; D007111:Immunity, Cellular; D009169:Mycobacterium tuberculosis / Q000276:immunology; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D011993:Recombinant Fusion Proteins; D013601:T-Lymphocytes / Q000276:immunology* / Q000637:transplantation*; D018088:Tuberculosis, Multidrug-Resistant / Q000628:therapy*
chemical_list: D016207:Cytokines; D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins
keywords: CAR; Mtb; T-cells; adoptive cell therapy; host-directed therapy